| Literature DB >> 30480031 |
Jean-Jacques Lemaire1,2, Anna Sontheimer1,2, Bruno Pereira3, Jérôme Coste1,2, Sarah Rosenberg2, Catherine Sarret2, Guillaume Coll1,2, Jean Gabrillargues4,2, Betty Jean4, Thierry Gillart5, Aurélien Coste1, Basile Roche2, Antony Kelly6, Bénédicte Pontier1,2, Fabien Feschet2.
Abstract
OBJECTIVE: The efficacy of deep brain stimulation in disorders of consciousness remains inconclusive. We investigated bilateral 30-Hz low-frequency stimulation designed to overdrive neuronal activity by dual pallido-thalamic targeting, using the Coma Recovery Scale Revised (CRS-R) to assess conscious behavior.Entities:
Year: 2018 PMID: 30480031 PMCID: PMC6243378 DOI: 10.1002/acn3.648
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Characteristics of the five patients
| Clinical consciousness status, gender, age (year), handedness; time elapsed since initial injury | Neurologic status | Surgery | Comorbidities | Diagnosis | Date | |
|---|---|---|---|---|---|---|
| P1 | UWS, male, 32, right handed; 12 years and 2 months | hypertonic quadriplegia predominant on right‐side; flexion or extension of upper limbs, and extension of lower limbs; chewing | May 2012, replacement of right VAS by left VPS (SC valve); July 2012, DBS surgery | right VAS, tracheostomy and gastrostomy post injury | traumatic head injury; left intracerebral hematoma; intraventricular and subarachnoid hemorrhage; multiple cerebral contusions; hydrocephalus | Dec 1999 |
| P2 | MCS‐, female, 62, right handed; 1 year and 2 months | hypertonic triplegia, left hemibody and right lower limb; flexion of lower limbs, and extension of the left upper limb; chewing | November 2012, replacement of right VAS by left VPS (SC valve); Dec 2012, DBS surgery | right VAS, gastrostomy, tracheostomy, right cranioplasty, and left neurogenic paraosteopathy (lower limbs) post hemorrhage; essential hypertension; migraine; hepatitis C; cataract right eye | rupture of right sylvian aneurysm; endovascular occlusion; intracerebral hematoma, intraventricular and subarachnoid hemorrhage; right sylvian artery vasospasm; right decompressive craniectomy; hydrocephalus | July 2011 |
| P3 | MCS‐, male, 24, left handed; 3 years and 1 month | hypertonic triplegia, left hemibody and right lower limb; flexion of the lower limbs and the left upper limb | November 2012, repair of right cranioplasty and repositioning ofVPS valve in the SC region; March 2013, DBS surgery | bilateral decompressive craniotomy followed by cranioplasty, right VPS, bilateral pulmonary embolism, tracheostomy and gastrostomy post injury; multidrug‐resistant bacteria; depression and schizophrenia without medication; neurogenic pain of the right inferior limb; pollen allergy | traumatic head injury; brain edema; right and left subdural hemorrhage; cervical spine injury and C2 fracture; hydrocephalus; pneumothorax | Nov 2009 |
| P4 | MCS‐, female, 22, right handed; 4 years | quadriplegia; flaccid paralysis of axial muscles and lower limbs; slight hypertonia of the upper limbs; chewing | Jan 2015, DBS surgery | tracheostomy, gastrostomy, lobar pneumonias (multidrug‐resistant bacteria) and suspected partial epileptic seizure post injury; unstable diabetes mellitus type 1; asthmatic bronchitis | traumatic head injury; polytrauma; bradycardia and asystole with 15 min of cardiopulmonary resuscitation; subarachnoid hemorrhage; multiple cerebralcontusions; bilateral pneumothorax; right pulmonary embolism | Nov 2010 |
| P5 | MCS‐, female, 47, right handed; 2 years and 3 months | hypertonic quadriplegia predominant on left; trismus; chewing; grunt | May 2015, DBS surgery | right VPS, tracheostomy and gastrostomy post injury; chronic consumption of alcohol and tobacco; chronic depression; eczema and keratitis in 2014‐2015; pollen allergy | rupture of right internal carotid artery termination aneurysm; endovascular occlusion; right frontal hematoma, intraventricular and subarachnoid hemorrhage; hydrocephalus | Dec 2012 |
VAS, ventriculoatrial shunt; VPS, ventriculoperitoneal shunt; SC subclavicular; UWS, Unresponsive Wakefulness Syndrome; MCS‐, Minimally Conscious State minus (patient demonstrating pursuit eye movement, ability to localize (and orient) noxious stimuli, and appropriate movements or affective behaviors).49
Figure 1Enrolment of patients. MCS, Minimally Conscious State; UWS, Vegetative State; EU, European Union.
Figure 2Contacts. (A) Deep brain targets and electrode positioning: Example (P1) of right and left targeted structures, pallidum (blue) and thalamus (pink) and location of effective (used in chronic stimulation; blue segments) contacts: top, T1 axial slice (4 mm above the anterior‐posterior commissure plane; inlays, clockwise from top left, Inversion‐Recovery sequence, FDG, and color‐coded diffusion tensor map); bottom, coregistered (with preoperative imaging) postoperative CT‐Scan, axial slice going through the center of the two effective contacts of the left thalamus, inlays, top‐right, sagittal and coronal slices going through the effective contacts within the thalamus. (B) Contact locations: Contacts (number, from distal to proximal, right from 0 to 3, left from 4 to 11) within the pallidum (blue) and thalamus (pink) of the 5 patients (P): superior view of 3D (semi‐transparent) anatomical structures, the effective contacts (numbers) are displayed as blue segments; background axial T1‐weighted MRI slice (inverted gray scale) going through anterior‐posterior commissure (ACPC) plane; *coil artefact; R, right.
Figure 3FDG methods. (A) FDG normalization: Baseline (left column) and DBS‐ON (intermediate column) normalized FDG, and DBS‐ON minus Baseline normalized FDG variation (right column), example for P1: top row (4 mm above the anterior‐posterior commissure plane), left and intermediate columns (inlay, raw FDG slices), standardized uptake values of cerebral metabolic rate of glucose normalized by cerebral global mean (CGM) activity (red, above CGM; blue, below CGM), and right column, variation map (green, increase; beige, decrease); bottom row, 3D rendering (superior and inferior views) of normalized data (R, right hemisphere). (B) FDG metabolism by cortical region and area: Top row, cortical areas and regions: internal area (light gray) with prefrontal ventromedial (PFVM), precuneal (PreCun), cingulate anterior (CingAnt), intermediate (CingInt) and posterior (posterior, retrosplenial and isthmus; CingPost) and temporo mesial para hippocampal (T5) cortices; external area (dark gray) with prefrontal dorsolateral (PFDL), ventrolateral (PFVL) and dorsomedial (PFDM), sensorimotor central (SMC) and paracentral (SMpc), parietal superior (Pa1) and inferior (Pa2), occipital lateral (OcLa) and medial (OcMe), temporal T1 (T1), T2 (T2), T3 (T3) and fusiform gyrus (T4) cortices; other area (white) with prefrontal orbital (PForbi) and polar (PFpo), temporopolar (Tpo) and cerebellar (Cerb) cortices. Bottom row, specification of FDG activities by region: example P1, right hemisphere; bold underlined increased activity (upward variation).
Mean CRS‐R scores during baseline, DBS‐ON, CO‐ON and CO‐OFF phases (the first period of the crossover phase is highlighted in gray); values are expressed as mean ± SD (number of assessments)
| Patient | Baseline | DBS‐ON | CO‐ON | CO‐OFF |
|---|---|---|---|---|
| P1 | 6.1 ± 1.3 (15) | 8.4 ± 1.8 (41) | 7.3 ± 1.9 (11) | 8.6 ± 2.0 (11) |
| P2 | 9.6 ± 2.7 (17) | 9.5 ± 1.5 (34) | 10.3 ± 1.3 (11) | 8.5 ± 1.9 (8) |
| P3 | 11.7 ± 1.6 (18) | 13.8 ± 2.2 (40) | 15.1 ± 1.9 (7) | 14.0 ± 3.4 (10) |
| P4 | 4.8 ± 1.8 (57) | 4.3 ± 1.8 (28) | 3.9 ± 1.6 (11) | 6.6 ± 1.5 (14) |
| P5 | 4.2 ± 3.3 (34) | 3.0 ± 1.7 (27) | 4.7 ± 2.0 (15) | 5.1 ± 2.4 (10) |
| All | 6.3 ± 3.5 (141) | 8.4 ± 4.2 (170) | 7.5 ± 4.1 (55) | 8.4 ± 3.7 (53) |
| All ‐ P5 | 6.9 ± 3.3 (107) | 9.4 ± 3.8 (143) | 8.6 ± 4.2 (40) | 9.2 ± 3.5 (43) |
Significant difference (P < 0.05) with baseline
Significant difference (P < 0.05) of CO‐ON with CO‐OFF.
Open‐eye state at night during baseline, DBS‐ON, CO‐ON and CO‐OFF phases (the first period of the crossover phase is highlighted in gray); values are expressed in number of observations (out of number of assessments; and percentage)
| Patient | Baseline | DBS‐ON | CO‐ON | CO‐OFF |
|---|---|---|---|---|
| P1 | 1 (14; 7.1%) | 6 (25; 24%) | 4 (14; 28.6%) | 2 (10; 20%) |
| P2 | 6 (24; 25%) | 1 (38; 2.6%) | 2 (8; 25%) | 0 (9; 0%) |
| P3 | 11 (16; 68.8%) | 1 (40; 2.5%) | 1 (6; 16.7%) | 2 (13; 15.4%) |
| P4 | 2 (14; 14.3%) | 3 (22; 13.6%) | 3 (13; 23.1%) | 3 (6; 50%) |
| P5 | n.a. | |||
| All ‐ P5 | 20 (68; 29.4%) | 11 (125; 8.8%) | 10 (41; 24.4%) | 7 (38; 18.4%) |
Significant difference (P < 0.05) with baseline.